Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by JACOB MANDEL and JOHN FREDERICK DE GROOT.
JACOB MANDEL
Connection Strength
5.891
JOHN FREDERICK DE GROOT
  1. External Control Arms and Data Analysis Methods in Nonrandomized Trial of Patients With Glioblastoma. JAMA Oncol. 2023 07 01; 9(7):1006.
    View in: PubMed
    Score: 0.946
  2. IDH mutation status and the development of venous thromboembolism in astrocytoma patients. J Neurol Sci. 2021 Aug 15; 427:117538.
    View in: PubMed
    Score: 0.821
  3. Effect of health disparities on overall survival of patients with glioblastoma. J Neurooncol. 2019 Apr; 142(2):365-374.
    View in: PubMed
    Score: 0.695
  4. Highlighting the need for reliable clinical trials in glioblastoma. Expert Rev Anticancer Ther. 2018 10; 18(10):1031-1040.
    View in: PubMed
    Score: 0.670
  5. Inability of positive phase II clinical trials of investigational treatments to subsequently predict positive phase III clinical trials in glioblastoma. Neuro Oncol. 2018 01 10; 20(1):113-122.
    View in: PubMed
    Score: 0.647
  6. Impact of IDH1 mutation status on outcome in clinical trials for recurrent glioblastoma. J Neurooncol. 2016 08; 129(1):147-54.
    View in: PubMed
    Score: 0.580
  7. Update on anti-angiogenic treatment for malignant gliomas. Curr Oncol Rep. 2014 Apr; 16(4):380.
    View in: PubMed
    Score: 0.498
  8. Window-of-opportunity clinical trial of pembrolizumab in patients with recurrent glioblastoma reveals predominance of immune-suppressive macrophages. Neuro Oncol. 2020 04 15; 22(4):539-549.
    View in: PubMed
    Score: 0.189
  9. Treatment strategies for glioblastoma in older patients: age is just a number. J Neurooncol. 2019 Nov; 145(2):357-364.
    View in: PubMed
    Score: 0.183
  10. Disparities along the glioblastoma clinical trials landscape. Neuro Oncol. 2019 02 14; 21(2):285-286.
    View in: PubMed
    Score: 0.175
  11. Primary and secondary gliosarcomas: clinical, molecular and survival characteristics. J Neurooncol. 2015 Nov; 125(2):401-10.
    View in: PubMed
    Score: 0.138
  12. Leptomeningeal dissemination in glioblastoma; an inspection of risk factors, treatment, and outcomes at a single institution. J Neurooncol. 2014 Dec; 120(3):597-605.
    View in: PubMed
    Score: 0.128
  13. Survival outcome of early versus delayed bevacizumab treatment in patients with recurrent glioblastoma. J Neurooncol. 2014 Aug; 119(1):135-40.
    View in: PubMed
    Score: 0.125
  14. Pineal parenchymal tumor of intermediate differentiation: a single-institution experience. Neurooncol Pract. 2020 Dec; 7(6):613-619.
    View in: PubMed
    Score: 0.048
  15. Exclusion of patients with brain metastases from cancer clinical trials. Neuro Oncol. 2020 04 15; 22(4):577-579.
    View in: PubMed
    Score: 0.047
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.